DK1294390T3 - Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet - Google Patents
Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitetInfo
- Publication number
- DK1294390T3 DK1294390T3 DK01906632T DK01906632T DK1294390T3 DK 1294390 T3 DK1294390 T3 DK 1294390T3 DK 01906632 T DK01906632 T DK 01906632T DK 01906632 T DK01906632 T DK 01906632T DK 1294390 T3 DK1294390 T3 DK 1294390T3
- Authority
- DK
- Denmark
- Prior art keywords
- cop
- nervous system
- polypeptide
- polypeptides
- copolymer
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229920001577 copolymer Polymers 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 230000004112 neuroprotection Effects 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 210000005036 nerve Anatomy 0.000 abstract 2
- 210000000653 nervous system Anatomy 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 2
- 230000008929 regeneration Effects 0.000 abstract 2
- 238000011069 regeneration method Methods 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20979900P | 2000-06-07 | 2000-06-07 | |
| US62021600A | 2000-07-20 | 2000-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1294390T3 true DK1294390T3 (da) | 2006-04-03 |
Family
ID=26904524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01906632T DK1294390T3 (da) | 2000-06-07 | 2001-01-22 | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20020037848A1 (da) |
| EP (1) | EP1294390B1 (da) |
| JP (1) | JP4328090B2 (da) |
| KR (1) | KR20030007397A (da) |
| CN (1) | CN100438906C (da) |
| AT (1) | ATE314860T1 (da) |
| AU (1) | AU783031B2 (da) |
| CA (1) | CA2398277C (da) |
| CY (1) | CY1105263T1 (da) |
| DE (1) | DE60116467T2 (da) |
| DK (1) | DK1294390T3 (da) |
| ES (1) | ES2256200T3 (da) |
| IL (2) | IL150801A0 (da) |
| MX (1) | MXPA02007109A (da) |
| NZ (1) | NZ520282A (da) |
| WO (1) | WO2001093893A2 (da) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2005046719A1 (en) * | 2003-11-12 | 2005-05-26 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| IL153236A0 (en) * | 2000-06-05 | 2003-07-06 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| SI1459065T1 (sl) | 2001-12-04 | 2010-11-30 | Teva Pharma | Postopki za merjenje potentnosti glatiramer acetata |
| US7351686B2 (en) * | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| CN102580069B (zh) | 2003-01-07 | 2015-09-30 | 耶达研究及发展有限公司 | 用于治疗性免疫接种的含共聚物1的滴眼用疫苗 |
| JP4632953B2 (ja) * | 2003-09-29 | 2011-02-16 | 中外製薬株式会社 | Ｎｋ細胞に発現するタンパク質 |
| CA2540890A1 (en) * | 2003-10-03 | 2005-04-14 | Bayhill Therapeutics, Inc. | Treatment of demyelinating autoimmune disease with modified ordered peptides |
| SI1701730T1 (sl) * | 2003-12-09 | 2014-01-31 | Yeda Research And Development Co. Ltd. The Weizmann Institute Of Science | Postopek in cepivo, ki obsega kopolimer 1 za zdravljenje psihiatriäśnih motenj |
| EP1750742A2 (en) | 2004-05-07 | 2007-02-14 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| UA91029C2 (uk) | 2004-09-09 | 2010-06-25 | Тева Фармасьютікл Індастріз Лтд. | Спосіб отримання сумішей поліпептидів з використанням очищеної бромоводневої кислоти |
| ES2541780T3 (es) * | 2004-11-29 | 2015-07-24 | Yeda Research And Development Co., Ltd. | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 |
| EP2016095A2 (en) | 2006-04-13 | 2009-01-21 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
| US8193147B2 (en) | 2007-09-24 | 2012-06-05 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
| NZ585367A (en) | 2007-10-16 | 2012-12-21 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| WO2009063459A2 (en) * | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| ES2424692T3 (es) | 2009-08-20 | 2013-10-07 | Yeda Research And Development Co., Ltd. | Terapia con acetato de glatirámero a baja frecuencia |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| TR201818858T4 (tr) * | 2010-01-04 | 2019-01-21 | Mapi Pharma Ltd | Glati̇ramer asetat i̇çeren depo si̇stemi̇. |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| US20150238582A1 (en) | 2012-09-10 | 2015-08-27 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| DK3506921T3 (da) | 2016-08-31 | 2023-07-31 | Mapi Pharma Ltd | Depotsystemer, der omfatter glatirameracetat |
| JP7602322B2 (ja) | 2017-03-26 | 2024-12-18 | マピ ファーマ リミテッド | 進行型の多発性硬化症を治療するためのグラチラマーデポシステム |
| EP4340853A4 (en) * | 2021-05-20 | 2025-05-07 | Washington University | Neuroprotective compositions and methods |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| EP1054880A1 (en) * | 1998-02-13 | 2000-11-29 | Autoimmune, Inc. | TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES |
-
2001
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en not_active Ceased
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Ceased
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
-
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
-
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001093893A3 (en) | 2002-04-04 |
| WO2001093893A2 (en) | 2001-12-13 |
| KR20030007397A (ko) | 2003-01-23 |
| EP1294390A2 (en) | 2003-03-26 |
| CA2398277C (en) | 2013-09-03 |
| HK1058892A1 (zh) | 2004-06-11 |
| CN100438906C (zh) | 2008-12-03 |
| CA2398277A1 (en) | 2001-12-13 |
| IL150801A (en) | 2007-10-31 |
| IL150801A0 (en) | 2003-02-12 |
| CY1105263T1 (el) | 2010-03-03 |
| DE60116467T2 (de) | 2006-11-02 |
| JP4328090B2 (ja) | 2009-09-09 |
| AU783031B2 (en) | 2005-09-15 |
| JP2004507460A (ja) | 2004-03-11 |
| NZ520282A (en) | 2004-09-24 |
| ES2256200T3 (es) | 2006-07-16 |
| EP1294390B1 (en) | 2006-01-04 |
| ATE314860T1 (de) | 2006-02-15 |
| MXPA02007109A (es) | 2002-12-13 |
| DE60116467D1 (de) | 2006-03-30 |
| CN1462190A (zh) | 2003-12-17 |
| AU3451801A (en) | 2001-12-17 |
| US20020037848A1 (en) | 2002-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1294390T3 (da) | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet | |
| DK1248643T3 (da) | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi | |
| WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| IL256054A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
| ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
| HUP9904023A2 (hu) | Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban | |
| HRP20010877B1 (hr) | Pripravci za prevenciju i liječenje amiloidogenskih bolesti | |
| ATE255128T1 (de) | Peptid-immitierende substanzen in der krebstherapie | |
| DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
| AR045870A1 (es) | Terapia de combinacion para la infeccion de virus de hepatitis c | |
| DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| EP1351968A4 (en) | MUTATIONS IN THE ALPHA1 SUBUNIT OF THE NEURONAL GENE SODIUM CHANNEL, ASSOCIATED POLYPEPTIDES, AND TREATMENT OF GEFS + SYNDROME (GENERALIZED EPILEPSY WITH FEBRILIS + CRISIS) | |
| ATE466870T1 (de) | Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems | |
| DE68906066D1 (de) | Peptid und dessen salze und antiallergische peptidmittel, welche diese peptide enthalten. | |
| WO1996020950A3 (en) | Compositions and methods for treating rheumatoid arthritis | |
| ATE247965T1 (de) | Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung | |
| RU96114420A (ru) | Способ лечения больных с неврологическими проявлениями остеохондроза позвоночника | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
| RU2003115786A (ru) | Способ лечения пневмонии у новорожденных | |
| EA200000514A1 (ru) | Способ лечения эректильной дисфункции |